Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 38 min 41 sec ago

Cairn Diagnostics Launches FDA-Approved Spirulina Gastric Emptying Breath Test for Gastroparesis

Tue, 03/29/2016 - 13:33
Non-invasive and non-radioactive test can be administered in any clinical setting Analysis of patient breath samples performed in a CLIA-certified lab Validated against gastric scintigraphy BRENTWOOD, Tenn., March 29, 2016 -- (Healthcare Sales & M...
Diagnostics, Gastroenterology, Product Launch
Cairn Diagnostics, gastroparesis, 13C-Spirulina, Gastric Emptying

Lannett Receives FDA Approvals For Two Products

Tue, 03/29/2016 - 13:26
Company Expects to Launch Temolozomide Capsules Shortly PHILADELPHIA, March 29, 2016 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA...
Biopharmaceuticals, Generics, FDA
Lannett Company, Temolozomide, Potassium Chloride

Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding

Tue, 03/29/2016 - 13:20
SAN DIEGO, March 29, 2016 -- (Healthcare Sales & Marketing Network) -- Adamis Pharmaceuticals Corporation (ADMP) (“Company” or “Adamis”) announced today that it has entered into a definitive merger agreement (the “Agreement”) to acquire US Compounding, Inc...
Biopharmaceuticals, Mergers & Acquisitions
Adamis Pharmaceuticals, US Compounding, drug compounding

Via Surgical Ltd. Announces the Appointment of John Gomes as its Chief Commercial Officer

Tue, 03/29/2016 - 13:14
AMIRIM, Israel, March 29, 2016 -- (Healthcare Sales & Marketing Network) -- Via Surgical Ltd., a leading developer of novel surgical fixation technologies for mesh placement in hernia repair, announced today that it has appointed John Gomes as its Chief C...
Devices, Surgery, Personnel
Via Surgical, FasTouch, hernia repair

Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer

Mon, 03/28/2016 - 21:30
NEW YORK, NY--(Healthcare Sales & Marketing Network) - Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Michael T. L...
Biopharmaceuticals, Oncology, Personnel
Lion Biotechnologies, melanoma

Easy and Effective Functional Test for Pediatric Ophthalmology Assessment with RETeval Complete(TM) Touted by Early Adopters

Mon, 03/28/2016 - 13:48
GAITHERSBURG, Md., March 28, 2016 -- (Healthcare Sales & Marketing Network) -- Jim Datovech, President of LKC Technologies, Inc. said, "We are learning from a number of ophthalmologists just how fast, easy, and effective functional testing of the ret...
Devices, Ophthalmology
LKC Technologies, RETeval Complete, Electroretinogram

Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA(TM)

Mon, 03/28/2016 - 13:41
MILTON, Ontario, March 28, 2016 -- (Healthcare Sales & Marketing Network) -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that the U.S. Food and Dru...
Biopharmaceuticals, Cardiology, FDA
Aralez Pharmaceuticals, YOSPRALA, aspirin therapy

Glaukos iStent(R) Trabecular Micro-Bypass Stent Approved in Japan

Mon, 03/28/2016 - 13:34
Approved by the MHLW for Use in Combination with Cataract Surgery, iStent Will Be First-Ever Ab Interno Micro-Scale Glaucoma Device Available in Japan LAGUNA HILLS, Calif.--(Healthcare Sales & Marketing Network)--Glaukos Corporation (GKOS), an ophthalm...
Devices, Ophthalmology, Regulatory
Glaukos, iStent , glaucoma

First Human Results with V-Wave’s Interatrial Shunt Published in The Lancet

Mon, 03/28/2016 - 13:23
Early Experience in Class III Heart Failure Patients was Favorable CAESAREA, Israel--(Healthcare Sales & Marketing Network)--V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF), announced today ...
Devices, Cardiology
V-Wave, interatrial shunt, heart failure, V-Wave Shunt

Hemostemix Appoints Hardean E. Achneck, M.D. as Chief Medical Officer

Fri, 03/25/2016 - 14:15
TORONTO, ON--(Healthcare Sales & Marketing Network) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE: HEM) (OTCQX: HMTXF), a clinical-stage autologous cell therapy company, announced today the promotion of Hardean E. Achne...
Regenerative Medicine, Personnel
Hemostemix, stem cell, critical limb ischemia

Ajanta Pharma Announces the Launch of Levetiracetam Tablets

Thu, 03/24/2016 - 15:33
BRIDGEWATER, N.J., March 24, 2016 -- (Healthcare Sales & Marketing Network) -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces today the launch of Levetiracetam Immediate-Release Tablets (250mg, 500mg, 750mg, 1000mg), a b...
Biopharmaceuticals, Generics, Product Launch
Ajanta Pharma, Levetiracetam, Keppra, UCB Pharma

Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors

Thu, 03/24/2016 - 15:31
Experienced Corporate Director with Scientific and Financial Background to Chair JNP Audit Committee BOSTON, March 24, 2016 -- (Healthcare Sales & Marketing Network) -- Juniper Pharmaceuticals, Inc. (JNP) ("Juniper" or the "Company"...
Biopharmaceuticals, Personnel
Juniper Pharmaceuticals, CRINONE, progesterone

Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer

Thu, 03/24/2016 - 15:27
TOKYO and SAN FRANCISCO, March 24, 2016 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE:4503) and Medivation, Inc. (MDVN) today announced that the ARCHES (AR Inhibition with ChemoHormonal Therapy in Men with MEtastatic Castrate Sens...
Biopharmaceuticals, Oncology
Astellas Pharma, enzalutamide, Prostate Cancer

Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma

Thu, 03/24/2016 - 15:23
Updated guidelines recognize the ONIVYDE regimen as a standard-of-care for treatment of patients with post-gemcitabine metastatic pancreatic cancer CAMBRIDGE, Mass., March 24, 2016 -- (Healthcare Sales & Marketing Network) -- Merrimack Pharmaceuticals,...
Biopharmaceuticals, Oncology
Merrimack Pharmaceuticals, ONIVYDE, irinotecan, Pancreatic Cancer, NCCN

Tunitas Therapeutics Expands Management Team with Appointment of David J. King as Senior Vice President, Research

Wed, 03/23/2016 - 16:39
SOUTH SAN FRANCISCO, Calif., March 23, 2016 -- (Healthcare Sales & Marketing Network) -- Tunitas Therapeutics, Inc. today announced the appointment of David J. King, Ph.D. as Senior Vice-President, Research. Dr. King was formerly chief scientific officer ...
Biopharmaceuticals, Personnel
Tunitas Therapeutics

Perrigo And Allergan Announce First-To-Market Launch Of Store Brand OTC Equivalent To Mucinex(R) 1200mg ER Tablets

Wed, 03/23/2016 - 16:37
DUBLIN, March 23, 2016 -- (Healthcare Sales & Marketing Network) -- Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (AGN) today announced the launch of guaifenesin 1200mg extended-release tablets, the OTC store brand equivalent to Mucinex...
Biopharmaceuticals, Product Launch
Perrigo Company, Allergan, guaifenesin, Mucinex

Mirati Therapeutics Announces Promotion Of Jamie A. Donadio To Chief Financial Officer

Wed, 03/23/2016 - 16:32
SAN DIEGO, March 23, 2016 -- (Healthcare Sales & Marketing Network) -- Mirati Therapeutics, Inc. (MRTX) today announced the promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016. Mr. Donadio ...
Biopharmaceuticals, Oncology, Personnel
Mirati Therapeutics, immunotherapy

Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing

Wed, 03/23/2016 - 16:26
Additional Financing to Support Advancement of Programs in Glaucoma, Diabetic Macular Edema and Age-related Macular Degeneration RESEARCH TRIANGLE PARK, N.C., March 23, 2016 -- (Healthcare Sales & Marketing Network) -- Envisia Therapeutics, a clinical...
Biopharmaceuticals, Ophthalmology, Venture Capital
Envisia Therapeutics, ENV515, glaucoma

Roche Submits Filing to FDA For cobas(R) Procalcitonin (Pct) Assay to Help Clinicians Assess Response of Septic Patients to Treatment

Wed, 03/23/2016 - 16:20
INDIANAPOLIS, March 23, 2016 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) to the U.S. Food and Drug Administr...
Biopharmaceuticals, FDA
Roche Group, cobas, Procalcitonin, sepsis

EarlySense Targets Growth in Southeast Asia with New Distributor

Wed, 03/23/2016 - 16:16
Partnership with MyHealth Sentinel Strengthens EarlySense's Global Reach RAMAT GAN, Israel, March 23, 2016 -- (Healthcare Sales & Marketing Network) -- EarlySense, the market leader in contact-free monitoring solutions, today announced it has signed a ...
Devices, Monitoring, Distribution
EarlySense, myHealth Sentinel

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong